We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Handheld Device Shown to Detect Cancer

By HospiMedica staff writers
Posted on 30 Jul 2003
A handheld device based on military technology may represent a portable, quick, noninvasive way to detect cancer.

The lightweight plastic baton, called TRIMprob (tissue resonance interaction method), is similar to the metal detectors used to examine airline passengers. More...
The baton contains an antenna that generates an electromagnetic field at very low power, interacting with tissues at the microscopic level. A computer linked to the probe analyzes the amount of interference at different frequencies and displays results in real-time in an easily understandable graphical format. The TRIMprob analyzes the condition of tissues and organs, detects and localizes pathologies ranging from inflammatory conditions to cancer, and finds them at an early stage. The baton can be used while patients are dressed and comfortable, providing immediate results.

In clinical trials at the San Carlo Borromeo Hospital in Milan (Italy), TRIMprob was able to predict prostate tumors in 93% of cases that were later confirmed by biopsy. Trials are now underway in other Italian hospitals for breast, lung, colon-rectal, liver, and stomach abnormalities.

TRIMprob is based on patented technology developed by physicist Clarbruno Vedruccio for Galileo Avionica, a subsidiary of Finmeccanica S.p.A., (Rome, Italy; www.finmeccanica.it), Italy's largest defense and aerospace group. After designing a detector for nonmetallic land mines and plastic explosives, Dr. Vedruccio decided he might be able to locate diseased tissue in people. When tests were carried out, they were very encouraging.

"In a short period of time and with a noninvasive procedure, we can discover or exclude a neoplastic prostate pathology. It is particularly useful for mass screenings as the first approach to assess nonrisk patients from those who need more refined searches,” said Dr. Ulrico Jacobellis, chief of the department of urology at the Polyclinic Hospital (Bari, Italy), affiliated with the Lahey Clinic in Burlington (MA, USA). Dr. Jacobellis is also an adjunct professor of urology at the Tufts University School of Medicine.




Related Links:
Finmeccanica

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Digital Color Doppler Ultrasound System
MS22Plus
Hemostatic Agent
HEMOBLAST Bellows
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.